da-001
Small moleculeexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jan 15, 2025 (NCT06648850)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
TAAR1 agonist
- Alpha-1a adrenergic receptorAGONIST
ADRA1A agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06648850 | Phase 3 | Jan 15, 2025 | Applied Biology, Inc., Daniel Alain, Inc., Follea International Limited, University of Roma La Sapienza |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Applied Biology, Inc. | For profit | 1 | 1 | 1 | 2025 |
| Daniel Alain, Inc. | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Follea International Limited | For profit | 1 | 0 | 1 | 2025 |
| University of Roma La Sapienza | Academic/Hospital | 1 | 0 | 1 | 2025 |
4 organizations
Page 1 / 1